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In conclusion, we ascertained seven
Chinese individuals with NPPK and
identified four causative mutations in
SERPINB7, two of which were poly-
morphic present in normal Chinese indi-
viduals. NPPK was estimated to be one
of the most common types of autosomal-
recessive PPKs in China despite its
delayed recognition. Moreover, we con-
firmed that the recurrent nonsense muta-
tion c.796C4T, prevalent both in
Chinese and Japanese NPPK patients,
probably descended from the same
ancestor. Finally, mutation screening of
c.796C4T in SERPINB7 can serve as a
cost-effective diagnostic strategy in the
setting of Chinese and Japanese patients
with diffuse, nonmutilating-inherited
PPKs, but without distinctive clinical or
histopathological features.
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TO THE EDITOR
Atopic dermatitis (AD) is a common
chronic relapsing disease. There is a
considerable body of evidence support-
ing a genetic basis for AD (Bussman
et al., 2011; Ellinghaus et al., 2013).
Mutations in the Filaggrin (FLG) gene
have been consistently found to be
associated with AD in people of
European and Asian ancestry (Brown
and McLean, 2012). More than 40 FLG
loss-of-function mutations have been
described in Europeans and Asians
(Brown and McLean, 2012). However,
FLG loss-of-function mutations have not
commonly been found in Africans or
African Americans (Winge et al., 2011a;
Brown and McLean, 2012; Margolis
et al., 2012). Loss-of-function mutations
in exon 3 of FLG result in diminished or
absent filaggrin protein, most often due
to a premature stop codon or a frame-
shift mutation resulting in a stop codon
further downstream. Interestingly, the
absence of profilaggrin protein (precur-
sor of filaggrin) has also been noted in
keratohyalin granules in the majority of
individuals with ichthyosis vulgaris of
European and Asian ancestry (Fleckman
and Brumbaugh, 2002; Perusquia-Ortiz
et al., 2013; Thyssen et al., 2013).
FLG is located on chromosome 1q21
in a region called the epidermal differ-
entiation complex. It is part of a family
of genes that code for S100-fused-like
proteins (SFTP). The SFTPs include the
proteins profilaggrin (coded by FLG),
hornerin (HRNR), filaggrin-2 (FLG2),
repetin (RPTN), cornulin (CRNN), tri-
chohyalin (TCHH), and trichohyalin-like 1
(TCHHL1; Henry et al., 2012). TheseAccepted article preview online 7 March 2014; published online 10 April 2014
Abbreviations: AD, atopic dermatitis; FLG, Filaggrin; MAF, minor allelic frequency; SFTP, S100-fused-like
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genes are very similar to one another
with respect to structure and function,
and lie in close proximity to each other
in the epidermal differentiation complex
(Marenholz et al., 2011; Henry et al.,
2012; Pellerin et al., 2013). On the basis
of previous experiences with FLG, it has
been hypothesized that a stop-gain (null)
mutation in exon 3 of any of the SFTP
genes will result in decreased or absent
protein production (Marenholz et al.,
2011; Henry et al., 2012; Margolis
et al., 2014).
The goal of this study was to identify
stop-gain variants in FLG and closely
related genes in African Americans with
AD from the Pediatric Eczema Elective
Registry (PEER; Margolis et al., 2012).
From this cohort we randomly
selected 60 subjects for whole-exome
sequencing to ensure sufficient power
to detect variants with a minor allelic
frequency (MAF) of greater than 3%.
Sequencing was performed by Ambry
Genetics (Aliso Viejo, CA) using whole
exome–targeted enrichment by Agilent
SureSelectXT Human All Exon 50Mb kit.
Quality assessment revealed that most
samples were above 50% on target and
mean coverage per gene was excellent.
The libraries were indexed using 100
base paired ends and processed using
Illumina HiSeq2000 at 100 coverage
per exon. Data were assessed using a
pipeline generated at the University of
Pennsylvania based on the best prac-
tices protocol from the Broad Institute
(Cambridge, MA). This report focused
on stop-gain mutations of exon 3 (i.e.,
loss-of-function mutations) in the SFTP
genes because of their likely functional
relevance (Marenholz et al., 2011;
Brown and McLean, 2012; Henry
et al., 2012). Taqman allelic discrimina-
tion assays were created for any newly
identified FLG loss-of-function mutations,
which were then used to genotype
an additional random sample of 100
African-American PEER children.
Sequencing of the SFTP genes in 60
self-reported (ancestry previously
confirmed with ancestral informative
markers (Margolis et al., 2012))
African-American children with AD
revealed a total of 289 variants in FLG,
107 variants in FLG2, 339 variants in
HRNR, 4 variants in RPTN, 37 variants
in CRNN, 88 variants in TCHH, and 14
variants in TCHHL1. However, very few
variants resulted in a premature stop
codon in exon 3 (Table 1). Each of the
three newly identified FLG stop-gain
mutations, Q570X, R3409X and
S3707X, were observed only once.
S2392X and S2377X in FLG2 were
noted 1 and 16 times, respectively. In
TCHHL1, the variant Q294X was noted
twice. All subjects were heterozygous
for the mutations. The MAF for variants
noted once, twice and 16 times were
0.008, 0.017, and 0.133, respectively.
Next, we used Taqman-based allelic
discrimination assays to evaluate the
three FLG mutations, Q570X, R3409X,
and S3707X, in an additional 100
African-American PEER children. How-
ever, none of these variants could be
detected in other members of our cohort.
This report is from the largest whole-
exome sequencing study of African
Americans with AD performed to date.
Here we have reported results specific
to the SFTP genes. We identified a few
new null mutations, albeit the ones in
FLG had low MAFs. The MAFs noted for
S2377X (FLG2) and Q294X (TCHHL1)
vary from the healthy subjects in the
1000 Genomes database (The 1000
Genomes Project Consortium, 2012;
Table 1). S2377X was seen about half
as frequently in our cohort compared
with that in the healthy 1000 Genomes
African population; whereas Q294X,
although more common in our cohort,
still had a low MAF (i.e., MAF¼0.017),
suggesting that these variants may not
be clinically important with respect to
incident AD.
Our findings are in agreement with
those of Winge et al. (2011a), who also
failed to detect common FLG loss-of-
function mutations in people of African
ancestry with AD. Our study does have
limitations in that we focused only on
exon 3 stop-gain mutations in genes.
We did not assess copy number varia-
tions. We also did not assay protein
function. Another point to be noted is
that as most African Americans have their
origins in West Africa; our findings may
not generalize to everyone with African
ancestry. However, based on the experi-
ences of others as well as those from our
study, which is the largest whole-exome
study of African Americans with AD, it
seems unlikely that FLG stop-gain muta-
tions have a prominent role with respect
to incident AD in African Americans
children (Winge et al., 2011b; Thaswer-
Esmail et al., 2014).
The study was approved by the
University of Pennsylvania Institutional
Review Board. The study was con-
ducted according to Declaration of
Helsinki Principles. All participants pro-
vided written informed consent.













FLG Stop-gain G A FLG:NM_002016:exon3:c.1708C4T:p.Q570X 0.008 — —
FLG Stop-gain G A FLG:NM_002016:exon3:c.10225C4T:p.R3409X 0.008 — —
FLG Stop-gain G T FLG:NM_002016:exon3:11120C4A:p.S3707X 0.008 — —
FLG2 Stop-gain G T FLG2:NM_001014342:exon3:c.7130C4A:p.S2377X 0.133 0.29 rs12568784
FLG2 Stop-loss C G FLG2:NM_001014342:exon3:c.7175G4C:p.S2392X 0.008 0.01 rs150529054
TCHHL1 Stop-gain G A TCHHL1:NM_001008536:exon3:c.880C4T:p.Q294X 0.017 0.01 rs61749316
Abbreviations: dbSNP, Single-Nucleotide Polymorphism Database; MAF, minor allele frequency.
DJ Margolis et al.
Exome Sequencing of Filaggrin and Related Genes
www.jidonline.org 2273
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This study was funded by R01-AR0056755 from
the National Institute of Arthritis Musculoskeletal
and Skin Diseases, a grant from Valeant Pharma-
ceuticals for the PEER study, and a grant from the
Breast Cancer Research Foundation (Nathanson)
for informatics analysis.
David J. Margolis1,2,5, Jayanta Gupta1,5,
Andrea J. Apter3, Ole Hoffstad1,
Maryte Papadopoulos1,
Tim R. Rebbeck1, Bradley Wubbenhorst4
and Nandita Mitra1
1Department of Biostatistics and Epidemiology,
Perelman School of Medicine, University of
Pennsylvania, Philadelphia, Pennsylvania, USA;
2Department of Dermatology, Perelman School
of Medicine, University of Pennsylvania,
Philadelphia Pennsylvania, USA; 3Department of
Medicine, Perelman School of Medicine,
University of Pennsylvania, Philadelphia
Pennsylvania, USA and 4Abramson Cancer
Center, Perelman School of Medicine, University
of Pennsylvania, Philadelphia Pennsylvania, USA
E-mail: margo@upenn.edu
5These two authors share first authorship.
REFERENCES
Brown SJ, McLean WH (2012) One remarkable
molecule: filaggrin. J Invest Dermatol 132:
751–62
Bussman C, Weidinger S, Novak N (2011) Genet-
ics of atopic dermatitis. J German Soc Der-
matol 9:670–9
Ellinghaus D, Baurecht H, Esparza-Gordillo J et al.
(2013) High-density genotyping study inden-
tifies four new susceptibility loci for atopic
dermatitis. Nat Genet 45:808–12
Fleckman P, Brumbaugh S (2002) Absence of
granular layer and keratohylin define a mor-
phologically distinct subset of individuals with
ichthyosis vulgaris. Exper Dermatol 11:327–36
Henry J, Toulza E, Hsu CY et al. (2012) Update on
the epidermal differentiation complex. Front
Biosci 17:1517–32
Marenholz I, Rivera VA, Esparza-Gordillo J et al.
(2011) Association screening in the Epidermal
Differentiation Complex (EDC) identifies an
SPRR3 repeat number variant as a risk factor
for eczema. J Investig Dermatol 131:1644–9
Margolis DJ, Apter AJ, Gupta J et al. (2012) The
persistence of atopic dermatitis and Filaggrin
mutations in a US longitudinal cohort.
J Allergy Clin Immunol 130:912–7
Margolis DJ, Gupta J, Apter AJ et al. (2014)
Filaggrin-2 variation is associated wtih more
persistent atopic dermatitis in African American
subjects. J Allergy Clin Immunol 133:784–9
Pellerin L, Henry J, Hsu CY et al. (2013) Defects in
filaggrin-like proteins in both lesional and
nonlesional atopic skin. J Allergy Clin Immu-
nol 131:1094–102
Perusquia-Ortiz AM, Oji V, Sauerland MC et al. (2013)
Complete filaggrin deficiency in ichthyosis vul-
garis is associated with only moderate changes in
epidermal permeability barrier function profile.
J Eur Acad Dermatol Venereol 27:1552–8
Thaswer-Esmail F, Jakasa I, Todd G et al. (2014) South
African amaXhosa patient with atopic dermatitis
have decreased levels of filaggrin breakdown
products but no loss-of-function mutations in
filaggrin. J Allergy Clin Immunol 133:280–2
The 1000 Genomes Project Consortium (2012)
An integrated map of genetic variation from
1,092 human genomes. Nature 491:56–65
Thyssen JP, Godoy-Gijon E, Elias PM (2013)
Ichthyosis vulgaris: the filaggrin mutation dis-
ease. Br J Dermatol 168:155–8
Winge MC, Bilcha KD, Lieden A et al. (2011a) Novel
filaggrin mutation but no other loss-of-function
variants found in Ethiopian patients with atopic
dermatitis. Br J Dermatol 165:1074–80
Winge MC, Bilcha KD, Lieden A et al. (2011b) Novel
filaggrin mutation but no other loss-of-function
variants found in Ethiopian patients with atopic
dermatitis. Br J Dermatol 165:1074–80
A New Lamin A Mutation Associated with Acrogeria
Syndrome
Journal of Investigative Dermatology (2014) 134, 2274–2277; doi:10.1038/jid.2014.158; published online 24 April 2014
TO THE EDITOR
Acrogeria (OMIM#201200), first des-
cribed in 1940 (Gottron, 1940), is
a form of skin atrophy combined
with mottled hyperpigmentation and
subcutaneous tissue atrophy giving
an aged appearance. The pathogenesis
of acrogeria seems heterogeneous, as
abnormal biosynthesis of type III colla-
gen is suspected in some cases, making
Gottron-type acrogeria and vascular-
type Ehlers–Danlos syndrome (vEDS,
OMIM#130050) allelic diseases (Pope
et al., 1996; Jansen et al., 2000;
Hashimoto et al., 2004).
Several clinical features of acrogeria
recall the dermatologic defects observed
in Hutchinson–Gilford progeria syndrome
(HGPS OMIM#176670), mandibuloacral
dysplasia type A (MADAOMIM#248370),
or mandibuloacral dysplasia type B
(MADB, OMIM #608612) phenotypes,
known to be caused by Lamins A/C
defects, due to mutations either in the
LMNA gene that encodes them or in the
ZMPSTE24 gene, which encodes a pro-
tease involved in Lamin A processing
(Novelli et al., 2002; De Sandre-
Giovannoli et al., 2003; Eriksson et al.,
2003; Ahmad et al., 2010). Lamins are
nuclear intermediate filaments that are
involved in nuclear architecture and
functions including chromatin organiza-
tion or DNA replication, transcription,
and repair, reviewed in Prokocimer
et al., 2009.
The patient affected with acrogeria
was born in 1969 from a healthy mother
and a probably affected father, who was
reported by the patient to have the same
skin aspect and had a mitral and aortic
valve replacement. The patient has a
brother and a son who are not affected.
At the age of 36 years, he was referred
to our department for ‘‘prematurely
aged’’ appearance. He presented with
a thin nose and translucent skin on the
face (Figure 1a, A). The distal portion of
the lower limbs seemed lipodystrophic
and the patient presented short clavicles
(Figure 1a, B). Translucent skin of the
arms and abdomen had pigmentation
abnormalities (Figure 1a, B, C). The
hands and the feet showed atrophic
dermis and loss of subcutaneous fat
(Figure 1a, B, D). The hands had a veryAccepted article preview online 1 April 2014; published online 24 April 2014
Abbreviations: HGPS, Hutchinson–Gilford progeria syndrome; MAD, mandibuloacral dysplasia; RT-PCR,
reverse transcription–PCR; vEDS, vascular-type Ehlers–Danlos syndrome
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